Bimekizumab Lowers Uveitis Rates in Axial Spondyloarthritis

In patients with axial spondyloarthritis, bimekizumab — a dual interleukin-17A/F inhibitor — showed a lower incidence rate of uveitis, suggesting protective effects against acute anterior uveitis.
Medscape Medical News

source https://www.medscape.com/viewarticle/bimekizumab-lowers-uveitis-rates-axial-spondyloarthritis-2024a1000fli?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

A case report of pudendal arteries angioplasty with sirolimus drug-coated balloon and drug-eluting stent associated with intracavernous autologous peripheral blood mononuclear cells injection for untreatable vasculogenic erectile dysfunction.